Biochemical detection of left-ventricular systolic dysfunction

Lancet

Volumn 351, Issue 9095, 1998, Pages 9-13

  McDonagh, T A ^a   Robb, S D ^b   Murdoch, D R ^b   Morton, J J ^b   Ford, I ^b   Morrison, C E ^b   Tunstall Pedoe, H ^b   McMurray, J J V ^b   Dargie, H J ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

EID: 0032477567     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03034-1     Document Type: Article

References (26)

1. 1 McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Engl J Med 1971; 285: 781-87.
2. 2 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
3. 3 McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-33.
4. 4 The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
5. 5 SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
6. 6 Wheeldon N, MacDonald T, Flucker CJ, McKendrick A, McDevitt D, Struthers AD. Echocardiography for chronic heart failure in the community. Q J Med 1993; 86: 17-24.
7. 7 Glenbotski CC, Dixon JE, GibsonTR. Secretion of atrial natriuretic factor (1-98) by primary cardiac myocytes. J Biol Chem 1988; 263: 16073-81.
8. 8 Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-29.
9. 9 Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-09.
10. 10 Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of pro atrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 6: 605-10.
11. 11 Wei CH, Heublein DM, Perella MA, et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88: 1004-49.
12. 12 Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator of angiotensin converting enzyme inhibition after myocardial infarction. Lancet 1993; 341: 1109-13.
13. 13 Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane ventriculography. Circulation 1979; 60: 547-55.
14. 14 Rose GA, Blackburn H, Gillum RF, Princas RJ. Cardiovascular survey methods, 2nd edn. Geneva: WHO Monograph Series, no 56.
15. 15 Land CC, Coutie WJ, Khong TK, Choy AMJ, Struthers AD. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens 1991; 9: 779-882.
16. 16 Heublein DM, Heser DW, Edwards BS, et al. N-terminal (1-25) atrial natriuretic factor in human congestive heart failure: a marker for endogenous secretion. J Am Coll Cardiol 1989; 13: 9A.
17. 17 Hanley JA, McNeill BJ. The meaning and use of the area under a receiver operator characteristic (ROC) curve. Radiology 1982; 143: 29-36.
18. 18 Yamamoto K, Burnett JC, Jougasaki M, et al. The relative value of the natriuretic peptides as markers for detecting abnormal ventricular structure and function. J Am Coll Cardiol 1996; 69A: 723-21.
19. 19 Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-37.
20. 20 Omland T, Aakvaag A, Bonargee VVS, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction. Circulation 1996; 93: 1963-69.
21. 21 Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in the assessment of acute dyspnoea. Lancet 1994; 343: 40-44.
22. 22 Choy AJ, Darbar D, Lang CC, et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994; 72: 16-22.
23. 23 Davidson NC, Coutie WJ, Struthers AD. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. Circulation 1995; 91: 1276.
24. 24 Hall C, Aaberge L, Stokke O. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. Circulation 1995; 91: 911.
25. 25 Jacobsen SJ, Bergstralh EJ, Guess HA, et al. Predictive properties of serum prostate-specific antigen testing in a community-based setting. Arch Intern Med 1996; 156: 2462-68.
26. 26 Swets JA, Getty DJ, Pickett RM, D'Orsi CJ, Seltzer SE, McNeill BJ. Enhancing and evaluating diagnostic accuracy. Med Decis Making Lancet 1998; 351: 28-31